B. Riley Expects Lower Earnings for Centessa Pharmaceuticals

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Equities research analysts at B. Riley lowered their Q1 2025 earnings estimates for shares of Centessa Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.36). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($2.01) EPS and FY2027 earnings at ($2.33) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04.

Several other research firms also recently weighed in on CNTA. Guggenheim reiterated a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday. They set an “overweight” rating and a $38.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $27.71.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $14.38 on Monday. The company’s 50-day moving average is $16.46 and its two-hundred day moving average is $16.43. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -9.40 and a beta of 1.54. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09.

Insider Activity

In related news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the completion of the transaction, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. This trade represents a 6.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the sale, the general counsel now directly owns 118,265 shares in the company, valued at $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock valued at $4,309,568 over the last quarter. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after purchasing an additional 660 shares during the period. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. Barclays PLC grew its position in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after purchasing an additional 5,316 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.